August 2026 Research Update

This month, the clearest treatment signal was that fenfluramine showed benefits across multiple ways of measuring seizure burden, including convulsive seizures and status epilepticus. The picture for cenobamate was different: in a broad group of severe childhood epilepsies it often helped, but Dravet syndrome stood out as having less sustained benefit. Together, these studies add detail about where certain medicines may or may not fit, while also showing that responses can differ by syndrome and by patient subgroup. [1] [2] [3]

When data from three randomized trials were pooled, fenfluramine reduced monthly convulsive seizure frequency compared with placebo in most subgroups, and it also improved a clinician-rated global change measure. The reduction was clearly seen in children aged 4 years and older, while the under-4 subgroup did not reach statistical significance in this analysis. The same pooled work reported longer stretches without convulsive seizures for many participants taking fenfluramine than for those on placebo, which matters because it reflects day-to-day breathing room between major seizures. [1]

In routine-care records focused on status epilepticus (a prolonged seizure emergency), fenfluramine exposure was linked to a substantially lower incidence of these episodes in a group of 61 people with genetically confirmed Dravet syndrome. The same study reported that stiripentol exposure was linked to shorter status epilepticus duration, while cannabidiol was not linked to a clear change in duration in their models. This helps separate two practical questions families often care about: how often prolonged emergencies happen, and how long they last when they do occur. [2]

For cenobamate, a retrospective multicenter study in Spain followed 152 children with developmental and epileptic encephalopathies and found high retention and substantial seizure reduction in many syndromes, but limited sustained benefit in Dravet syndrome. Safety issues were meaningful in this real-world sample, including treatment-emergent seizure worsening in 10.5% and discontinuation due to adverse events in 10.5%. This adds to the idea that results seen across mixed epilepsy groups may not translate equally to Dravet syndrome, and that tolerability can be a deciding factor in long-term use. [3]

Safety reporting was most detailed for fenfluramine in the pooled randomized trial analysis, where adverse events were common in both fenfluramine and placebo groups and most resolved by the end of the studies. Ten of 216 fenfluramine-treated participants (about 5%) discontinued treatment because of adverse events, and no valvular heart disease or pulmonary arterial hypertension was reported in these trials. This provides some reassurance within the limits of trial duration and the ages studied (2 to 18 years). [1]

For families, these studies strengthen a consistent message that fenfluramine is linked to lower convulsive seizure burden and may also relate to fewer status epilepticus emergencies, although the status epilepticus finding comes from retrospective data rather than a randomized comparison. The cenobamate results are mainly informative as context: it appeared broadly helpful in other severe childhood epilepsies, but Dravet syndrome had less sustained benefit and a notable rate of side effects in this dataset. What remains uncertain is how these findings compare head-to-head with other Dravet-specific options, and how well they predict longer-term outcomes beyond the study windows. [1] [2] [3]

This month added practical tools and shared language for talking about Dravet syndrome beyond seizures. A new caregiver-administered interview showed very strong reliability for capturing developmental and behavioral difficulties, and an expert panel highlighted that non-seizure issues can affect health and daily life across the lifespan. Together, these studies push the field toward measuring outcomes that families experience directly, not only seizure frequency. [4] [5]

The D-DAND interview was tested in 123 people with Dravet syndrome ages 3 to 41, and caregivers gave very similar answers when they repeated the interview later (very high test-retest reliability). The scores lined up closely with some established questionnaires but not others, suggesting it may capture Dravet-specific patterns that standard tools can miss. This matters because it offers a more consistent way to describe changes in everyday functioning over time, even when seizure counts do not tell the whole story. [4]

An Italian expert panel produced consensus statements stressing that non-seizure issues such as cognition, behavior, sleep, communication, motor skills, and adaptive abilities can shape outcomes across life in Dravet syndrome and Lennox-Gastaut syndrome. The panel also stated that fenfluramine may have meaningful benefits across selected non-seizure domains, while noting that evidence on non-seizure outcomes is mixed and needs longer-term, syndrome-specific measurement. This supports the idea that future studies should track non-seizure changes in a structured way, rather than assuming seizure control automatically captures overall benefit. [5]

For patients and caregivers, the main change this month is better recognition and measurement of difficulties that often drive the biggest day-to-day burden, like sleep, behavior, and learning. The new D-DAND interview may matter later because it could make research and follow-up conversations more consistent and more focused on what families notice at home, but it is not itself a treatment. The consensus statements do not prove that any medicine improves non-seizure issues, yet they clarify that measuring those outcomes directly is important and that current evidence is uneven. [4] [5]

This month, several studies looked at what it is like to reach a Dravet diagnosis, live with the broader impact on quality of life, and take part in research. The studies point in the same direction: delays and system barriers still happen, and family wellbeing and logistics play a large role in daily burden. At the same time, caregivers often describe trial participation as positive despite stress and uncertainty, which helps explain why some families seek research options while others hesitate. [6] [7] [8] [9]

In a European survey mapping 45 patient pathways, the median time from seizure onset to formal Dravet diagnosis was 11 months, and a quarter of children were not diagnosed until after 23 months of age. Reported bottlenecks included delays in referral to Dravet-experienced care and the time needed to get genetic testing results. The same survey reported that Dravet-specific antiseizure medicines were started a median of 3 months after diagnosis, with notable delays in some cases. [6]

A smaller retrospective report of 18 children with SCN1A-related suspected Dravet syndrome described very early seizure onset and found that all tested variants were de novo (new in the child) among those with segregation results. It also noted that some children received sodium channel-blocking antiseizure medicines before genetic confirmation, and seizures worsened in several of those cases. This underscores why timing of genetic answers can matter in real life, because medication choices may be made before the diagnosis is confirmed. [7]

A large parent-proxy survey in China across 28 rare diseases found that health-related quality of life was low in many conditions, with Dravet syndrome among the diseases reported to have particularly low scores. Lower quality of life was linked to factors such as diagnostic delays, lack of treatment, more comorbidities, and worse family functioning and parental wellbeing. Because the survey is cross-sectional, it cannot prove which factor causes which outcome, but it helps show how strongly family and system factors can track with day-to-day wellbeing. [8]

A caregiver survey of 44 families whose children had participated in Dravet randomized trials reported that enrollment was usually suggested by the treating pediatric neurologist and that access to new treatments and hope were common motivations. Caregivers described positive overall experiences, but also frequent stress, fear about not completing the trial, and the emotional weight of uncertainty, along with practical barriers like fitting frequent appointments into daily life. Reported regret and feelings of solitude after the trial were low. This helps explain the real tradeoffs families weigh when considering research participation. [9]

For families, these studies mainly add context rather than changing medical care: they document that delays to diagnosis and delays to Dravet-specific medicines still occur, and they describe reasons why. They also reinforce that quality of life in Dravet syndrome is shaped by more than seizures, including comorbidities and family stressors, which may matter now for understanding the full burden. What remains uncertain is how much diagnostic timelines differ across countries and care settings, since some data came from specialist centers or from surveys rather than complete health system records. [6] [7] [8] [9]

This month included one laboratory study that looked closely at brain cell shape in a Dravet mouse model, rather than testing a treatment in people. It reported that certain cerebellar nerve cells showed signs of reduced branching and less mature spine shapes in Scn1a+/- mice. This kind of work does not predict symptoms in any one person, but it helps map where in the brain Dravet-related changes may occur. [10]

Using a viral labeling approach to highlight small numbers of Purkinje cells (a cerebellar cell type important for coordination), the researchers compared cells across cerebellar regions and ages and then compared Dravet-model mice with controls. In Scn1a+/- mice, Purkinje cells had reduced dendritic complexity and spines that were longer with smaller heads, while spine density was similar to controls. In plain language, the cells looked less elaborate and their small connection points looked less mature, which could be relevant to understanding non-seizure features that involve cerebellar circuits. [10]

For patients and caregivers, this is early-stage research in mice, so it is not used to diagnose Dravet syndrome or to choose treatments. Its value is in building a clearer biological picture of Dravet syndrome beyond seizures by pointing to specific brain circuits and cell features that may be altered. What remains uncertain is how these cell-shape differences relate to specific day-to-day challenges in people, and whether changing them would improve outcomes. [10]